Saara-Anne Azizi, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esterases | 3 | 2024 | 88 | 0.900 |
Why?
|
| Acyltransferases | 2 | 2022 | 305 | 0.840 |
Why?
|
| Acrylamides | 1 | 2021 | 259 | 0.660 |
Why?
|
| Olfaction Disorders | 1 | 2020 | 224 | 0.590 |
Why?
|
| MAP Kinase Signaling System | 1 | 2023 | 1480 | 0.530 |
Why?
|
| Acylation | 3 | 2024 | 97 | 0.470 |
Why?
|
| Brain Diseases | 1 | 2020 | 1546 | 0.370 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 3700 | 0.360 |
Why?
|
| Antiviral Agents | 5 | 2022 | 3048 | 0.340 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 1085 | 0.310 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 2571 | 0.280 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2022 | 1967 | 0.230 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3094 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3216 | 0.200 |
Why?
|
| Host-Pathogen Interactions | 2 | 2022 | 1448 | 0.200 |
Why?
|
| Neurons | 2 | 2020 | 9435 | 0.200 |
Why?
|
| Stroke | 2 | 2024 | 9720 | 0.200 |
Why?
|
| Ethylamines | 1 | 2021 | 17 | 0.200 |
Why?
|
| Coronavirus OC43, Human | 1 | 2021 | 18 | 0.190 |
Why?
|
| Apoptosis | 1 | 2017 | 9478 | 0.190 |
Why?
|
| Papain | 1 | 2021 | 65 | 0.190 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2021 | 188 | 0.180 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2023 | 613 | 0.180 |
Why?
|
| Lipoylation | 1 | 2021 | 86 | 0.180 |
Why?
|
| Maleimides | 1 | 2021 | 112 | 0.180 |
Why?
|
| Epidermal Growth Factor | 1 | 2023 | 699 | 0.180 |
Why?
|
| Lipids | 2 | 2023 | 3330 | 0.180 |
Why?
|
| Bystander Effect | 1 | 2020 | 89 | 0.170 |
Why?
|
| Cannabidiol | 1 | 2022 | 118 | 0.170 |
Why?
|
| Peroxiredoxins | 1 | 2019 | 51 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 2 | 2022 | 931 | 0.160 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2021 | 366 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 328 | 0.160 |
Why?
|
| Peptide Hydrolases | 1 | 2021 | 616 | 0.150 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 752 | 0.150 |
Why?
|
| Protein Interaction Mapping | 1 | 2021 | 614 | 0.150 |
Why?
|
| Brain | 3 | 2024 | 27097 | 0.130 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 647 | 0.120 |
Why?
|
| Escherichia coli Proteins | 1 | 2021 | 1060 | 0.120 |
Why?
|
| RNA | 1 | 2024 | 2708 | 0.110 |
Why?
|
| Thiazoles | 1 | 2021 | 1517 | 0.110 |
Why?
|
| Indoles | 1 | 2021 | 1830 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2023 | 8303 | 0.100 |
Why?
|
| Epithelial Cells | 2 | 2022 | 3666 | 0.100 |
Why?
|
| Protein Transport | 1 | 2017 | 1959 | 0.100 |
Why?
|
| Vero Cells | 2 | 2022 | 482 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2022 | 3044 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 2223 | 0.080 |
Why?
|
| Models, Molecular | 1 | 2019 | 5413 | 0.080 |
Why?
|
| Virus Replication | 3 | 2022 | 2426 | 0.080 |
Why?
|
| Escherichia coli | 1 | 2021 | 4205 | 0.080 |
Why?
|
| Catalytic Domain | 2 | 2021 | 702 | 0.080 |
Why?
|
| Homeostasis | 1 | 2019 | 3318 | 0.080 |
Why?
|
| Mice | 4 | 2023 | 81324 | 0.080 |
Why?
|
| Proteins | 1 | 2023 | 5993 | 0.080 |
Why?
|
| Animals | 5 | 2023 | 168083 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 16947 | 0.060 |
Why?
|
| Hypertension | 1 | 2024 | 8537 | 0.060 |
Why?
|
| Humans | 13 | 2024 | 761098 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 11856 | 0.050 |
Why?
|
| Lung | 1 | 2020 | 9979 | 0.050 |
Why?
|
| Polyproteins | 1 | 2021 | 10 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2021 | 4250 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2021 | 464 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8663 | 0.040 |
Why?
|
| Endoribonucleases | 1 | 2022 | 226 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2021 | 590 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2024 | 1081 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 12145 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2022 | 433 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2021 | 233 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 428 | 0.040 |
Why?
|
| Interferons | 1 | 2022 | 702 | 0.040 |
Why?
|
| Virus Internalization | 1 | 2022 | 496 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2021 | 1222 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2020 | 23415 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2021 | 1768 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 1331 | 0.030 |
Why?
|
| Benzamides | 1 | 2021 | 1370 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 1936 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 2227 | 0.030 |
Why?
|
| Binding Sites | 1 | 2021 | 5993 | 0.030 |
Why?
|
| Piperidines | 1 | 2021 | 1656 | 0.030 |
Why?
|
| Viral Load | 1 | 2021 | 3328 | 0.020 |
Why?
|
| Cell Survival | 1 | 2021 | 5776 | 0.020 |
Why?
|
| Pyridines | 1 | 2021 | 2872 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 9518 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 10755 | 0.020 |
Why?
|
| Mitochondria | 1 | 2019 | 3620 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 20120 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 30006 | 0.010 |
Why?
|
| Female | 1 | 2022 | 392458 | 0.000 |
Why?
|